特発性頭蓋内圧亢進症治療薬の世界市場（～2026年）

• 英文タイトル：Global Idiopathic Intracranial Hypertension Therapeutics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY12296
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、98ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は特発性頭蓋内圧亢進症治療薬のグローバル市場について調査・分析したレポートです。種類別（アセタゾラミド、フロセミド、トピラマート、オクトレオチド）市場規模、用途別（病院薬局、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別特発性頭蓋内圧亢進症治療薬の競争状況、市場シェア
・世界の特発性頭蓋内圧亢進症治療薬市場：種類別市場規模 2015年-2020年（アセタゾラミド、フロセミド、トピラマート、オクトレオチド）
・世界の特発性頭蓋内圧亢進症治療薬市場：種類別市場規模予測 2021年-2026年（アセタゾラミド、フロセミド、トピラマート、オクトレオチド）
・世界の特発性頭蓋内圧亢進症治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、その他）
・世界の特発性頭蓋内圧亢進症治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、その他）
・北米の特発性頭蓋内圧亢進症治療薬市場分析：米国、カナダ
・ヨーロッパの特発性頭蓋内圧亢進症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの特発性頭蓋内圧亢進症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の特発性頭蓋内圧亢進症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの特発性頭蓋内圧亢進症治療薬市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：AbbVie、Astellas Pharma、Cadila Healthcare、Johnson & Johnson Services、Merck、Mylan、Pfizer、Sanofi、Sun Pharmaceutical、Teva Pharmaceutical
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

A drug used to treat idiopathic intracranial hypertension.

Market Analysis and Insights: Global Idiopathic Intracranial Hypertension Therapeutics Market
The global Idiopathic Intracranial Hypertension Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Idiopathic Intracranial Hypertension Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Idiopathic Intracranial Hypertension Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Idiopathic Intracranial Hypertension Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Idiopathic Intracranial Hypertension Therapeutics market.

Global Idiopathic Intracranial Hypertension Therapeutics Scope and Market Size
Idiopathic Intracranial Hypertension Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Intracranial Hypertension Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Acetazolamide
Furosemide
Topiramate
Octreotide

Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Other

Based on regional and country-level analysis, the Idiopathic Intracranial Hypertension Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Idiopathic Intracranial Hypertension Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
AbbVie
Astellas Pharma
Cadila Healthcare
Johnson & Johnson Services
Merck
Mylan
Pfizer
Sanofi

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Intracranial Hypertension Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Acetazolamide
1.2.3 Furosemide
1.2.4 Topiramate
1.2.5 Octreotide
1.3 Market by Application
1.3.1 Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Application: 2020 VS 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Idiopathic Intracranial Hypertension Therapeutics Market Perspective (2015-2026)
2.2 Global Idiopathic Intracranial Hypertension Therapeutics Growth Trends by Regions
2.2.1 Idiopathic Intracranial Hypertension Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Idiopathic Intracranial Hypertension Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Idiopathic Intracranial Hypertension Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Intracranial Hypertension Therapeutics Players by Market Size
3.1.1 Global Top Idiopathic Intracranial Hypertension Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Idiopathic Intracranial Hypertension Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Intracranial Hypertension Therapeutics Revenue
3.4 Global Idiopathic Intracranial Hypertension Therapeutics Market Concentration Ratio
3.4.1 Global Idiopathic Intracranial Hypertension Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Intracranial Hypertension Therapeutics Revenue in 2019
3.5 Key Players Idiopathic Intracranial Hypertension Therapeutics Area Served
3.6 Key Players Idiopathic Intracranial Hypertension Therapeutics Product Solution and Service
3.7 Date of Enter into Idiopathic Intracranial Hypertension Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Idiopathic Intracranial Hypertension Therapeutics Breakdown Data by Type (2015-2026)
4.1 Global Idiopathic Intracranial Hypertension Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Idiopathic Intracranial Hypertension Therapeutics Forecasted Market Size by Type (2021-2026)

5 Idiopathic Intracranial Hypertension Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Idiopathic Intracranial Hypertension Therapeutics Historic Market Size by Application (2015-2020)
5.2 Global Idiopathic Intracranial Hypertension Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Idiopathic Intracranial Hypertension Therapeutics Market Size (2015-2026)
6.2 North America Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020)
6.3 North America Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020)
6.4 North America Idiopathic Intracranial Hypertension Therapeutics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada

7 Europe
7.1 Europe Idiopathic Intracranial Hypertension Therapeutics Market Size (2015-2026)
7.2 Europe Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020)
7.3 Europe Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020)
7.4 Europe Idiopathic Intracranial Hypertension Therapeutics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe

8 China
8.1 China Idiopathic Intracranial Hypertension Therapeutics Market Size (2015-2026)
8.2 China Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020)
8.3 China Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020)
8.4 China Idiopathic Intracranial Hypertension Therapeutics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific

9 Japan
9.1 Japan Idiopathic Intracranial Hypertension Therapeutics Market Size (2015-2026)
9.2 Japan Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020)
9.3 Japan Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020)
9.4 Japan Idiopathic Intracranial Hypertension Therapeutics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil

10 Southeast Asia
10.1 Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Size (2015-2026)
10.2 Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020)
10.3 Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020)
10.4 Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa

11Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Idiopathic Intracranial Hypertension Therapeutics Introduction
11.1.4 AbbVie Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020))
11.1.5 AbbVie Recent Development
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Details
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Idiopathic Intracranial Hypertension Therapeutics Introduction
11.2.4 Astellas Pharma Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.2.5 Astellas Pharma Recent Development
11.3 Cadila Healthcare
11.3.1 Cadila Healthcare Company Details
11.3.2 Cadila Healthcare Business Overview
11.3.3 Cadila Healthcare Idiopathic Intracranial Hypertension Therapeutics Introduction
11.3.4 Cadila Healthcare Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.3.5 Cadila Healthcare Recent Development
11.4 Johnson & Johnson Services
11.4.1 Johnson & Johnson Services Company Details
11.4.2 Johnson & Johnson Services Business Overview
11.4.3 Johnson & Johnson Services Idiopathic Intracranial Hypertension Therapeutics Introduction
11.4.4 Johnson & Johnson Services Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.4.5 Johnson & Johnson Services Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Idiopathic Intracranial Hypertension Therapeutics Introduction
11.5.4 Merck Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.5.5 Merck Recent Development
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Idiopathic Intracranial Hypertension Therapeutics Introduction
11.6.4 Mylan Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.6.5 Mylan Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Idiopathic Intracranial Hypertension Therapeutics Introduction
11.7.4 Pfizer Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.7.5 Pfizer Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Idiopathic Intracranial Hypertension Therapeutics Introduction
11.8.4 Sanofi Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.8.5 Sanofi Recent Development
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Company Details
11.9.2 Sun Pharmaceutical Business Overview
11.9.3 Sun Pharmaceutical Idiopathic Intracranial Hypertension Therapeutics Introduction
11.9.4 Sun Pharmaceutical Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.9.5 Sun Pharmaceutical Recent Development
11.10 Teva Pharmaceutical
11.10.1 Teva Pharmaceutical Company Details
11.10.2 Teva Pharmaceutical Business Overview
11.10.3 Teva Pharmaceutical Idiopathic Intracranial Hypertension Therapeutics Introduction
11.10.4 Teva Pharmaceutical Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
11.10.5 Teva Pharmaceutical Recent Development

12Analyst’s Viewpoints/Conclusions

13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Idiopathic Intracranial Hypertension Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Acetazolamide
Table 4. Key Players of Furosemide
Table 5. Key Players of Topiramate
Table 6. Key Players of Octreotide
Table 7. Global Idiopathic Intracranial Hypertension Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Idiopathic Intracranial Hypertension Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Idiopathic Intracranial Hypertension Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Regions (2015-2020)
Table 11. Global Idiopathic Intracranial Hypertension Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Regions (2021-2026)
Table 13. Idiopathic Intracranial Hypertension Therapeutics Market Market Trends
Table 14. Idiopathic Intracranial Hypertension Therapeutics Market Drivers
Table 15. Idiopathic Intracranial Hypertension Therapeutics Market Challenges
Table 16. Idiopathic Intracranial Hypertension Therapeutics Market Restraints
Table 17. Global Idiopathic Intracranial Hypertension Therapeutics Revenue by Players (2015-2020) (US$ Million)
Table 18. Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Players (2015-2020)
Table 19. Global Top Idiopathic Intracranial Hypertension Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Intracranial Hypertension Therapeutics as of 2019)
Table 20. Global Idiopathic Intracranial Hypertension Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Idiopathic Intracranial Hypertension Therapeutics Product Solution and Service
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 25. Global Idiopathic Intracranial Hypertension Therapeutics Market Size Share by Type (2015-2020)
Table 26. Global Idiopathic Intracranial Hypertension Therapeutics Revenue Market Share by Type (2021-2026)
Table 27. Global Idiopathic Intracranial Hypertension Therapeutics Market Size Share by Application (2015-2020)
Table 28. Global Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 29. Global Idiopathic Intracranial Hypertension Therapeutics Market Size Share by Application (2021-2026)
Table 30. North America Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 31. North America Idiopathic Intracranial Hypertension Therapeutics Market Share by Type (2015-2020)
Table 32. North America Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 33. North America Idiopathic Intracranial Hypertension Therapeutics Market Share by Application (2015-2020)
Table 34. North America Idiopathic Intracranial Hypertension Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 35. North America Idiopathic Intracranial Hypertension Therapeutics Market Share by Country (2015-2020)
Table 36. Europe Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 37. Europe Idiopathic Intracranial Hypertension Therapeutics Market Share by Type (2015-2020)
Table 38. Europe Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 39. Europe Idiopathic Intracranial Hypertension Therapeutics Market Share by Application (2015-2020)
Table 40. Europe Idiopathic Intracranial Hypertension Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 41. Europe Idiopathic Intracranial Hypertension Therapeutics Market Share by Country (2015-2020)
Table 42. China Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 43. China Idiopathic Intracranial Hypertension Therapeutics Market Share by Type (2015-2020)
Table 44. China Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 45. China Idiopathic Intracranial Hypertension Therapeutics Market Share by Application (2015-2020)
Table 46. China Idiopathic Intracranial Hypertension Therapeutics Market Size by Region (US$ Million) (2015-2020)
Table 47. China Idiopathic Intracranial Hypertension Therapeutics Market Share by Region (2015-2020)
Table 48. Japan Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 49. Japan Idiopathic Intracranial Hypertension Therapeutics Market Share by Type (2015-2020)
Table 50. Japan Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 51. Japan Idiopathic Intracranial Hypertension Therapeutics Market Share by Application (2015-2020)
Table 52. Japan Idiopathic Intracranial Hypertension Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 53. Japan Idiopathic Intracranial Hypertension Therapeutics Market Share by Country (2015-2020)
Table 54. Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 55. Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Share by Type (2015-2020)
Table 56. Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 57. Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Share by Application (2015-2020)
Table 58. Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 59. Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Share by Country (2015-2020)
Table 60. AbbVie Company Details
Table 61. AbbVie Business Overview
Table 62. AbbVie Product
Table 63. AbbVie Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 64. AbbVie Recent Development
Table 65. Astellas Pharma Company Details
Table 66. Astellas Pharma Business Overview
Table 67. Astellas Pharma Product
Table 68. Astellas Pharma Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 69. Astellas Pharma Recent Development
Table 70. Cadila Healthcare Company Details
Table 71. Cadila Healthcare Business Overview
Table 72. Cadila Healthcare Product
Table 73. Cadila Healthcare Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 74. Cadila Healthcare Recent Development
Table 75. Johnson & Johnson Services Company Details
Table 76. Johnson & Johnson Services Business Overview
Table 77. Johnson & Johnson Services Product
Table 78. Johnson & Johnson Services Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 79. Johnson & Johnson Services Recent Development
Table 80. Merck Company Details
Table 81. Merck Business Overview
Table 82. Merck Product
Table 83. Merck Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 84. Merck Recent Development
Table 85. Mylan Company Details
Table 86. Mylan Business Overview
Table 87. Mylan Product
Table 88. Mylan Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 89. Mylan Recent Development
Table 90. Pfizer Company Details
Table 91. Pfizer Business Overview
Table 92. Pfizer Product
Table 93. Pfizer Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 94. Pfizer Recent Development
Table 95. Sanofi Business Overview
Table 96. Sanofi Product
Table 97. Sanofi Company Details
Table 98. Sanofi Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 99. Sanofi Recent Development
Table 100. Sun Pharmaceutical Company Details
Table 101. Sun Pharmaceutical Business Overview
Table 102. Sun Pharmaceutical Product
Table 103. Sun Pharmaceutical Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 104. Sun Pharmaceutical Recent Development
Table 105. Teva Pharmaceutical Company Details
Table 106. Teva Pharmaceutical Business Overview
Table 107. Teva Pharmaceutical Product
Table 108. Teva Pharmaceutical Revenue in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020) (US$ Million)
Table 109. Teva Pharmaceutical Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Acetazolamide Features
Figure 3. Furosemide Features
Figure 4. Topiramate Features
Figure 5. Octreotide Features
Figure 6. Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Other Case Studies
Figure 10. Idiopathic Intracranial Hypertension Therapeutics Report Years Considered
Figure 11. Global Idiopathic Intracranial Hypertension Therapeutics Market Size (US$ Million), YoY Growth 2015-2026
Figure 12. Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Regions: 2020 VS 2026
Figure 13. Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Regions (2021-2026)
Figure 14. Global Idiopathic Intracranial Hypertension Therapeutics Market Share by Players in 2019
Figure 15. Global Top Idiopathic Intracranial Hypertension Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Intracranial Hypertension Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Idiopathic Intracranial Hypertension Therapeutics Revenue in 2019
Figure 17. North America Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. United States Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Canada Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Europe Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Germany Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. France Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. U.K. Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Italy Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Russia Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Nordic Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Rest of Europe Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Asia-Pacific Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. China Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Japan Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. South Korea Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Southeast Asia Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. India Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Australia Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Rest of Asia-Pacific Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Latin America Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Mexico Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Brazil Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Middle East & Africa Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Turkey Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Saudi Arabia Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. UAE Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Rest of Middle East & Africa Idiopathic Intracranial Hypertension Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. AbbVie Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 45. Astellas Pharma Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 46. Cadila Healthcare Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 47. Johnson & Johnson Services Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 48. Merck Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 49. Mylan Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 50. Pfizer Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 51. Sanofi Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 52. Sun Pharmaceutical Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 53. Teva Pharmaceutical Revenue Growth Rate in Idiopathic Intracranial Hypertension Therapeutics Business (2015-2020)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

以下、関連資料のご紹介

特発性頭蓋内圧亢進症治療の世界市場（～2026年）

Global Idiopathic Intracranial Hypertension Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12297 2020年11月25日 129Pages
当調査資料は特発性頭蓋内圧亢進症治療のグローバル市場について調査・分析したレポートです。種類別（アセタゾラミド、メタゾラミド、フロセミド、トピラマート、その他）市場規模、用途別（病院、クリニック、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア...

慢性血栓塞栓性肺高血圧症（CTEPH）の世界市場（～2026年）

Global Chronic Thromboembolic Pulmonary Hypertension Market Size, Status and Forecast 2020-2026
MRC2-11QY11373 2020年11月25日 99Pages
当調査資料は慢性血栓塞栓性肺高血圧症（CTEPH）のグローバル市場について調査・分析したレポートです。種類別（経胸壁心エコー検査（TTE）、換気灌流（V/Q）スキャン、肺血管造影、心臓カテーテル検査、コンピューター断層撮影（CT）肺血管造影、その他）市場規模、用途別（病院、外来手術センター、その他）...

特発性血小板減少性紫斑病（ITP）治療薬の世界市場（～2026年）

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Insights and Forecast to 2026
MRC2-11QY01539 2020年11月20日 111Pages
当調査資料は特発性血小板減少性紫斑病（ITP）治療薬のグローバル市場について調査・分析したレポートです。種類別（コルチコステロイド、静脈内免疫グロブリン（IVIG）、抗D免疫グロブリン、トロンボポエチン受容体作動薬（TPO-RA）、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北...

肺動脈性肺高血圧症（PAH）の世界市場（～2026年）

Global Pulmonary Arterial Hypertension (PAH) Market Size, Status and Forecast 2020-2026
MRC2-11QY04414 2020年11月20日 95Pages
当調査資料は肺動脈性肺高血圧症（PAH）のグローバル市場について調査・分析したレポートです。種類別（プロスタサイクリンおよびプロスタサイクリン類似体、SGC刺激剤、ERA、PDE-5）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イ...

頭蓋内出血診断・治療の世界市場（～2026年）

Global Intracranial Hemorrhage Diagnosis and Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12412 2020年11月25日 91Pages
当調査資料は頭蓋内出血診断・治療のグローバル市場について調査・分析したレポートです。種類別（装置、薬剤、その他）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、...

全身性特発性若年性関節炎治療の世界市場（～2026年）

Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04784 2020年11月20日 92Pages
当調査資料は全身性特発性若年性関節炎治療のグローバル市場について調査・分析したレポートです。種類別（アダリムマブバイオシミラー、カナキヌマブ、ゴリムマブ、トシリズマブバイオシミラー、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス...

慢性特発性骨髄線維症の世界市場（～2026年）

Global Chronic Idiopathic Myelofibrosis Market Size, Status and Forecast 2020-2026
MRC2-11QY11363 2020年11月25日 96Pages
当調査資料は慢性特発性骨髄線維症のグローバル市場について調査・分析したレポートです。種類別（化学療法、生物学的療法、その他）市場規模、用途別（病院、クリニック、研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、...

特発性低身長治療薬の世界市場（～2026年）

Global Idiopathic Short Stature Drug Market Insights and Forecast to 2026
MRC2-11QY01538 2020年11月20日 111Pages
当調査資料は特発性低身長治療薬のグローバル市場について調査・分析したレポートです。種類別（BBT-031、MMP-0201、ソマトロピン、ソマトロピンS、その他）市場規模、用途別（研究センター、病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、...

過活動膀胱治療薬の世界市場（～2026年）

Global Overactive Bladder Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY04131 2020年11月20日 99Pages
当調査資料は過活動膀胱治療薬のグローバル市場について調査・分析したレポートです。種類別（抗コリン作用薬、ミラベグロン、ボトックス）市場規模、用途別（特発性過活動膀胱、神経因性過活動膀胱）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国...

特発性肺線維症（IPF）の世界市場（～2026年）

Global Idiopathic Pulmonary Fibrosis Market Size, Status and Forecast 2020-2026
MRC2-11QY12298 2020年11月25日 95Pages
当調査資料は特発性肺線維症（IPF）のグローバル市場について調査・分析したレポートです。種類別（全身性コルチコステロイド、免疫抑制薬、チロシンキナーゼ阻害剤、抗線維化剤）市場規模、用途別（病院、クリニック、外来手術センター、学術・研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フ...

特発性頭蓋内圧亢進症治療の世界市場（～2026年） Idiopathic intracranial hypertension is characterized by a buildup of the cerebrospinal fluid causing increase in the blood volume in vessels surrounding the brain and increase in brain swelling. The increase in salt intake causes water retention in the body together with fat adding on to the calori…
肺動脈性肺高血圧症（PAH）の世界市場（～2026年） Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pulmonary Arterial Hypertension (PAH) S…
特発性血小板減少性紫斑病（ITP）治療薬の世界市場（～2026年） ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike. Increasing demand for combination ther…
慢性特発性骨髄線維症の世界市場（～2026年） Idiopathic myelofibrosis is a chronic myelo-proliferative disorder and characterized by abnormal mutation of stem cells. This abnormal mutation of stem cells and excessive production of platelets result in development of fibrous tissues within the bone-marrow. This factor would ultimately negatively…
頭蓋内出血診断・治療の世界市場（～2026年） Bleeding or haemorrhages loss of blood from the circulatory system which may be internal or external due to variety of conditions such as trauma, tissue damage due to surgery, accidents, cuts etc. Generally loss of 10–15% of the total blood volume does not cause serious mental problems and can be to…